Diabetic Eye Injection: A Shot for Life

DALLAS (Ivanhoe Newswire) – Diabetic retinopathy is the leading cause of blindness in American adults. Partially because it is often missed until it is too late. Now, a new treatment is helping save patients’ sight.
Sixty-eight year old Charles Cavill was in danger of losing his sight, but now, for the first time in years, he can play golf again. Cavill told Ivanhoe, “When you can’t make good contact with the ball because your vision’s not there, you learn not to play.”
Like many Americans with diabetes, the tiny blood vessels in Cavill’s eyes became damaged and the retinas swelled. He underwent laser surgery and cataract surgery in both eyes but he still needs injections of a steroid to control the swelling. Before Iluvien, the injections were administered monthly. But now, one injection is good for three years.
FDA-approved, Iluvien came on the market in March. It can be administered during an office visit, it’s long-lasting, and doctors say it is low risk even for patients with glaucoma and cataracts.


ILUVIEN is an intravitreal implant of fluocinolone acetonide and is the first DME treatment to deliver 36 months of continuous, low-dose corticosteroid with a single injection.
Fluocinolone acetonide is a corticosteroid, which may play an important role in addressing the inflammatory process associated with DME. Corticosteroids have been shown to inhibit inflammatory responses to a variety of inciting agents. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.
Read more: http://www.ksat.com/health/diabetic-eye-injection-a-shot-for-life
Source: KSAT 12